Logo

skin cancer

Castle Biosciences Q1 Revenues Grow 18 Percent

The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.

DermTech Posts 48 Percent Jump in Q1 Revenues

Despite the revenue increase, the La Jolla, California-based skin cancer diagnostics firm missed Wall Street's revenue and earnings expectations.

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members.

DermTech Q4 Revenues Jump 52 Percent, Miss Wall Street Estimate

The company's revenue gains were driven by higher sales of its noninvasive skin cancer tests.

Castle Biosciences Q4 Revenues Grow 45 Percent

The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.

Nov 16, 2021

Cancer Genomic Analysis Reveals Distinct Features in Tumors From Patients Under 50 Years Old

Nov 9, 2021

Dermtech Q3 Revenues Rise 122 Percent

Nov 8, 2021

Castle Biosciences Q3 Revenues Rise 54 Percent

Oct 27, 2021

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

Sep 16, 2021

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Aug 24, 2021

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

Aug 9, 2021

Castle Biosciences Q2 Revenues Rise 79 Percent

Jun 9, 2021

Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic

May 11, 2021

Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer
Premium

May 10, 2021

Castle Biosciences Q1 Revenues Up 31 Percent

Mar 11, 2021

Eye Color GWAS Leads to 50 New Loci, Underscoring Trait's Complexity

Mar 8, 2021

Castle Biosciences Q4 Revenues Down 2 Percent

Mar 5, 2021

DermTech Q4 Revenues Up 31 Percent

Feb 16, 2021

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

Feb 12, 2021

DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay

Jan 7, 2021

DermTech Prices $125M Public Offering of Common Stock

Jun 22, 2020

Genomic Study Reveals Recurrent Cutaneous Melanoma Alterations, Male-Specific Mutations

Jun 5, 2020

Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type

Apr 27, 2020

Cutaneous Melanoma Clues Found From Risky SNPs, Related Traits Analyses

Mar 9, 2020

DermTech Trying to Drum up Payor Coverage for Melanoma Test With Study Results
Premium

Breaking News
The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.